Enliven Therapeutics, Inc. (ELVN) Form 8-K — Aug 5, 2026
Enliven Therapeutics reported a Q2 2026 net loss of $32.5 million, wider than the $25.3 million loss a year earlier, as R&D spending rose to $29.0 million from $21.5 million. The clinical-stage biotech held $895.2 million in cash, cash equivalents and marketable securities at June 30, 2026, nearly double the $462.6 million at year-end 2025, which management expects to fund operations into 2030. The quarter's headline was positive Phase 1 data for ELVN-001 in chronic myeloid leukemia, with 61% overall major molecular response in the 80 mg once-daily Phase 1b cohort and 67% in patients with only one or two prior TKIs.
Key figures
- Total Assets
- 910223000
- Cash Position
- 895155000
- Cash runway
- into 2030
- Cash dec 31 2025
- 462621000
- Ga expense q2 2025
- 7093000
- Ga expense q2 2026
- 8213000
- Rnd expense q2 2025
- 21491000
- Rnd expense q2 2026
- 28996000
- Stockholders equity
- 895149000
- Phase3 dose selected
- 80 mg once daily
- Fast track designation
- Yes
- Mmr by 24wk 80mg cohort
- 48%
- Mmr overall 80mg cohort
- 61%
- Mmr by 24wk earlier line
- 55%
- Mmr overall earlier line
- 67%
- Phase1 patients enrolled
- 161
- Phase3 initiation timing
- second half of 2026
- Weighted avg shares q2 2025
- 52105000
- Weighted avg shares q2 2026
- 66172000
- Median treatment duration weeks
- 35
Price after filing
Close on the filing date to close N calendar days later (from $61.11). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.